HR Execs on the Move

Circle Pharma

www.circlepharma.com

 
Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.circlepharma.com
  • 280 Utah Avenue Suite 100
    South San Francisco, CA USA 94080
  • Phone: 650.392.0363

Executives

Name Title Contact Details

Similar Companies

Innovacon

Innovacon, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

QLT Inc

QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases. QLT`s head office is based in Vancouver, Canada and the company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT).

Cadila Pharmaceuticals

Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.

R.D. Laboratories

R.D. Laboratories is a Washington, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.